Document Detail

Design and in vitro evaluation of finasteride-loaded liquid crystalline nanoparticles for topical delivery.
MedLine Citation:
PMID:  23207960     Owner:  NLM     Status:  MEDLINE    
In this study, liquid crystalline nanoparticles (LCN) have been proposed as new carrier for topical delivery of finasteride (FNS) in the treatment of androgenetic alopecia. To evaluate the potential of this nanocarrier, FNS-loaded LCN was prepared by ultrasonication method and characterized for size, shape, in vitro release, and skin permeation-retention properties. The particle size ranged from 153.8 to 170.2 nm with a cubical shape and exhibited controlled release profile with less than 20% of the drug released in the first 24 h. The release profile was significantly altered with addition of different additives. Formulation with lower monoolein exhibited higher skin permeation with a flux rate of 0.061±0.005 μg cm(-2) h(-1) in 24 h. The permeation however, significantly increased with glycerol, propylene glycol, and polyethylene glycol 400, while it declined for the addition of oleic acid. A similar trend was observed with skin retention study. In conclusion, FNS-loaded LCN could be advocated as a viable alternative for oral administration of the drug.
Thiagarajan Madheswaran; Rengarajan Baskaran; Raj Kumar Thapa; Jeong Yeon Rhyu; Hye Yoon Choi; Jong Oh Kim; Chul Soon Yong; Bong Kyu Yoo
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-12-04
Journal Detail:
Title:  AAPS PharmSciTech     Volume:  14     ISSN:  1530-9932     ISO Abbreviation:  AAPS PharmSciTech     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-26     Completed Date:  2013-08-12     Revised Date:  2013-12-10    
Medline Journal Info:
Nlm Unique ID:  100960111     Medline TA:  AAPS PharmSciTech     Country:  United States    
Other Details:
Languages:  eng     Pagination:  45-52     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
5-alpha Reductase Inhibitors / administration & dosage,  pharmacology*
Administration, Topical
Drug Evaluation, Preclinical
Finasteride / administration & dosage,  pharmacology*
Mice, Hairless
Microscopy, Electron, Transmission
Particle Size
Reg. No./Substance:
0/5-alpha Reductase Inhibitors; 57GNO57U7G/Finasteride

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-Term Safety and Efficacy of Two Different Antimuscarinics, Imidafenacin and Solifenacin, for Tr...
Next Document:  Label-free electrophysiological cytometry for stem cell-derived cardiomyocyte clusters.